| Bioactivity | Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine[1]. | ||||||||||||
| Target | MK-1602 | ||||||||||||
| Name | Ubrogepant | ||||||||||||
| CAS | 1374248-77-7 | ||||||||||||
| Formula | C29H26F3N5O3 | ||||||||||||
| Molar Mass | 549.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Li CC, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021. |
Ubrogepant
CAS: 1374248-77-7 F: C29H26F3N5O3 W: 549.54
Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.